Compare SXC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | DBVT |
|---|---|---|
| Founded | 1960 | 2002 |
| Country | United States | France |
| Employees | 848 | 90 |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.2M | 850.9M |
| IPO Year | 2011 | 2014 |
| Metric | SXC | DBVT |
|---|---|---|
| Price | $9.71 | $9.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $9.50 | ★ $38.55 |
| AVG Volume (30 Days) | ★ 897.5K | 370.8K |
| Earning Date | 10-27-2026 | 10-28-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $1,600,300,000.00 | $5,636,000.00 |
| Revenue This Year | $0.68 | N/A |
| Revenue Next Year | N/A | $1,630.16 |
| P/E Ratio | $98.35 | ★ N/A |
| Revenue Growth | 10.30 | ★ 35.77 |
| 52 Week Low | $5.52 | $8.63 |
| 52 Week High | $10.68 | $26.19 |
| Indicator | SXC | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 37.63 |
| Support Level | $9.14 | N/A |
| Resistance Level | $9.79 | $14.90 |
| Average True Range (ATR) | 0.28 | 0.46 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 4.81 | 46.45 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.